Adenosine signaling in normal and sickle erythrocytes and beyond

Microbes and Infection

Volumn 14, Issue 10, 2012, Pages 863-873

  Zhang, Yujin ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

2,3 Diphosphoglycerate; Adenosine; Adenosine A 2B receptor; Adenosine deaminase; Malaria; Sickle cell disease

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENINE NUCLEOTIDE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GLYCOLIC ACID; HEMOGLOBIN S; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PEGADEMASE; PSB 1115; PURINERGIC RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CORPUS CAVERNOSUM; DEGRADATION; DEOXYGENATION; DISEASE COURSE; ERYTHROCYTE; GENE EXPRESSION; HEMOLYSIS; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; LUNG DISEASE; MALARIA; NATURAL KILLER T CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PENILE FIBROSIS; PHENOTYPE; PRIAPISM; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; SICKLE CELL; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SICKLE CELL TRAIT; TISSUE INJURY; VASCULAR SMOOTH MUSCLE; WILD TYPE;

2,3-DIPHOSPHOGLYCERATE; ADENOSINE; ANEMIA, SICKLE CELL; ANIMALS; ANOXIA; ERYTHROCYTES; ERYTHROCYTES, ABNORMAL; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION;

MUS;

EID: 84863844259     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.05.005     Document Type: Article

References (70)

1. Madigan C., Malik P. Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Exp. Rev. Mol. Med. 2006, 8:1-23.
2. Urbinati F., Madigan C., Malik P. Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias. Exp. Rev. Mol. Med. 2006, 8:1-26.
3. Rees D.C., Williams T.N., Gladwin M.T. Sickle-cell disease. Lancet 2011, 376:2018-2031.
4. Hsu L.L., Champion H.C., Campbell-Lee S.A., Bivalacqua T.J., Manci E.A., Diwan B.A., Schimel D.M., Cochard A.E., Wang X., Schechter A.N., Noguchi C.T., Gladwin M.T. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007, 109:3088-3098.
5. Gladwin M.T., Vichinsky E. Pulmonary complications of sickle cell disease. N. Engl. J. Med. 2008, 359:2254-2265.
6. Akinsheye I., Klings E.S. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J. Cell. Physiol. 2010, 224:620-625.
7. Herrick J.B. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch. Intern. Med. 1910, 6:517-521.
8. Pauling L., Itano H.A., et al. Sickle cell anemia a molecular disease. Science 1949, 110:543-548.
9. Ingram V.M. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 1956, 178:792-794.
10. Chang J.C., Kan Y.W. Antenatal diagnosis of sickle cell anaemia by direct analysis of the sickle mutation. Lancet 1981, 2:1127-1129.
11. Hebbel R.P. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991, 77:214-237.
12. de Montalembert M. Advances in sickle cell disease. Bull. Acad. Nat. Med. 2008, 192:1375-1381. discussion 1381.
13. Kato G.J., Martyr S., Blackwelder W.C., Nichols J.S., Coles W.A., Hunter L.A., Brennan M.L., Hazen S.L., Gladwin M.T. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br. J. Haematol. 2005, 130:943-953.
14. Kato G.J., Onyekwere O.C., Gladwin M.T. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr. Hematol. Oncol. 2007, 24:159-170.
15. Sebastiani P., Nolan V.G., Baldwin C.T., Abad-Grau M.M., Wang L., Adewoye A.H., McMahon L.C., Farrer L.A., Taylor J.G.t., Kato G.J., Gladwin M.T., Steinberg M.H. A network model to predict the risk of death in sickle cell disease. Blood 2007, 110:2727-2735.
16. Gladwin M.T. Prevalence, risk factors and mortality of pulmonary hypertension defined by right heart catheterization in patients with sickle cell disease. Expert Review Hematology 2011, 4:593-596.
17. Ballas S.K. Current issues in sickle cell pain and its management, hematology/the education program of the American Society of Hematology. Am. Soc. Hematol. 2007, 97-105.
18. Eltzschig H.K., Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 364:656-665.
19. Colgan S.P., Taylor C.T. Hypoxia: an alarm signal during intestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 2011, 7:281-287.
20. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53:527-552.
21. Fredholm B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007, 14:1315-1323.
22. Tanneur V., Duranton C., Brand V.B., Sandu C.D., Akkaya C., Kasinathan R.S., Gachet C., Sluyter R., Barden J.A., Wiley J.S., Lang F., Huber S.M. Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes. Faseb J. 2006, 20:133-135.
23. Levano-Garcia J., Dluzewski A.R., Markus R.P., Garcia C.R. Purinergic signalling is involved in the malaria parasite Plasmodium falciparum invasion to red blood cells. Purinergic Signalling 2010, 6:365-372.
24. Akkaya C., Shumilina E., Bobballa D., Brand V.B., Mahmud H., Lang F., Huber S.M. The Plasmodium falciparum-induced anion channel of human erythrocytes is an ATP-release pathway. Pflugers Arch. 2009, 457:1035-1047.
25. Colgan S.P., Eltzschig H.K., Eckle T., Thompson L.F. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2006, 2:351-360.
26. Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., Polosukhin V., Wain J., Karimi-Shah B.A., Kim N.D., Hart W.K., Pardo A., Blackwell T.S., Xu Y., Chun J., Luster A.D. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 2008, 14:45-54.
27. Zhang Y., Dai Y., Wen J., Zhang W., Grenz A., Sun H., Tao L., Lu G., Alexander D.C., Milburn M.V., Carter-Dawson L., Lewis D.E., Zhang W., Eltzschig H.K., Kellems R.E., Blackburn M.R., Juneja H.S., Xia Y. Detrimental effects of adenosine signaling in sickle cell disease. Nat. Med. 2011, 17:79-86.
28. Hebbel R.P., Osarogiagbon R., Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004, 11:129-151.
29. Paszty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr. Opin. Hematol. 1997, 4:88-93.
30. Paszty C., Brion C.M., Manci E., Witkowska H.E., Stevens M.E., Mohandas N., Rubin E.M. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997, 278:876-878.
31. Poillon W.N., Kim B.C. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 1990, 76:1028-1036.
32. Poillon W.N., Kim B.C., Labotka R.J., Hicks C.U., Kark J.A. Antisickling effects of 2,3-diphosphoglycerate depletion. Blood 1995, 85:3289-3296.
33. Poillon W.N., Kim B.C., Welty E.V., Walder J.A. The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. Arch. biochemistry Biophysics 1986, 249:301-305.
34. Scheinman J.I. Sickle cell disease and the kidney. Nat. Clin. Pract. 2009, 5:78-88.
35. Eckle T., Faigle M., Grenz A., Laucher S., Thompson L.F., Eltzschig H.K. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008, 111:2024-2035.
36. Eckle T., Grenz A., Laucher S., Eltzschig H.K. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J. Clin. Invest. 2008, 118:3301-3315.
37. Burnett A.L. Therapy insight: priapism associated with hematologic dyscrasias. Nat. Clin. Pract. Urol. 2005, 2:449-456.
38. Bennett N., Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J. Sex. Med. 2008, 5:1244-1250.
39. Nolan V.G., Wyszynski D.F., Farrer L.A., Steinberg M.H. Hemolysis-associated priapism in sickle cell disease. Blood 2005, 106:3264-3267.
40. Abbasi S., Su B., Kellems R.E., Yang J., Xia Y. The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation. J.Biol. Chem. 2005, 280:36737-36746.
41. Yonezawa A., Sakurada S., Furukawa K., Kimura Y. Adenosine and adenosine triphosphate. Nippon Rinsho 2002, 60(Suppl. 6):52-56.
42. Noto T., Inoue H., Mochida H., Kikkawa K. Role of adenosine and P2 receptors in the penile tumescence in anesthetized dogs. Eur. J. Pharmacol. 2001, 425:51-55.
43. Filippi S., Mancini M., Amerini S., Bartolini M., Natali A., Mancina R., Forti G., Ledda F., Maggi M. Functional adenosine receptors in human corpora cavernosa. Int. J. Androl. 2000, 23:210-217.
44. Shalev M., Staerman F., Allain H., Lobel B., Saiag B. Stimulation of P2y purinoceptors induces, via nitric oxide production, endothelium-dependent relaxation of human isolated corpus cavernosum. J. Urol. 1999, 161:955-959.
45. Sharifzadeh M., Zarrindast M.R., Samini M. Effects of adenosine analogues on apomorphine-induced penile erection in rats. Gen. Pharmacol. 1995, 26:1785-1790.
46. Kilic S., Salih M., Anafarta K., Baltaci S., Kosar A. Adenosine: a new agent in the diagnosis of impotence. Int. J. Impot. Res. 1994, 6:191-198.
47. Hsu L., Diwan B., Ward J.M., Noguchi C.T. Pathology of "Berkeley" sickle-cell mice includes gallstones and priapism. Blood 2006, 107:3414-3415.
48. Mi T., Abbasi S., Zhang H., Uray K., Chunn J.L., Xia L.W., Molina J.G., Weisbrodt N.W., Kellems R.E., Blackburn M.R., Xia Y. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J. Clin. Invest. 2008, 118:1491-1501.
49. Dai Y., Zhang Y., Phatarpekar P., Mi T., Zhang H., Blackburn M.R., Xia Y. Adenosine signaling, priapism and novel therapies. J. Sex. Med. 2009, 6(Suppl. 3):292-301.
50. Phatarpekar P.V., Wen J., Xia Y. Role of adenosine signaling in penile erection and erectile disorders. J. Sex. Med. 2010, 7:3553-3564.
51. Burnett A.L., Bivalacqua T.J. Priapism: current principles and practice. Urol. Clin. North Am. 2007, 34:631-642. viii.
52. Wen J., Jiang X., Dai Y., Zhang Y., Tang Y., Sun H., Mi T., Kellems R.E., Blackburn M.R., Xia Y. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J. Sex. Med. 2010, 7:3011-3022.
53. Wen J., Grenz A., Zhang Y., Dai Y., Kellems R.E., Blackburn M.R., Eltzschig H.K., Xia Y. A2B adenosine receptor contributes to penile erection via PI3K/AKT signaling cascade-mediated eNOS activation. Faseb J. 2011, 25:2823-2830.
54. Wallace K.L., Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010.
55. Hershfield M.S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol 1995, 76:S228-S232.
56. Blackburn M.R., Aldrich M., Volmer J.B., Chen W., Zhong H., Kelly S., Hershfield M.S., Datta S.K., Kellems R.E. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J. Biol. Chem. 2000, 275:32114-32121.
57. Allison A.C. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans. R. Soc.Trop. Med. Hyg. 1954, 48:312-318.
58. Tsaras G., Owusu-Ansah A., Boateng F.O., Amoateng-Adjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am. J. Med. 2009, 122:507-512.
59. Key N.S., Derebail V.K. Sickle-cell trait: novel clinical significance, hematology/the education program of the American society of hematology. Am. Soc. Hematol. 2010, 418-422.
60. Allison A.C. Protection afforded by sickle-cell trait against subtertian malarial infection. Br. Med. J. 1954, 1:290-294.
61. Allison A.C. Genetic factors in resistance to malaria. Ann. New York Acad. Sci. 1961, 91:710-729.
62. Aidoo M., Terlouw D.J., Kolczak M.S., McElroy P.D., ter Kuile F.O., Kariuki S., Nahlen B.L., Lal A.A., Udhayakumar V. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002, 359:1311-1312.
63. Allison A.C. Genetic control of resistance to human malaria. Curr. Opin. Immunol. 2009, 21:499-505.
64. Lopez C., Saravia C., Gomez A., Hoebeke J., Patarroyo M.A. Mechanisms of genetically-based resistance to malaria. Gene 2010, 467:1-12.
65. Fairhurst R.M., Bess C.D., Krause M.A. Abnormal PfEMP1/knob display on Plasmodium falciparum-infected erythrocytes containing hemoglobin variants: fresh insights into malaria pathogenesis and protection. Microbes Infect. 2012, 14:851-862.
66. Ayi K., Liles W.C., Gros P., Kain K.C. Adenosine triphosphate depletion of erythrocytes simulates the phenotype associated with pyruvate kinase deficiency and confers protection against Plasmodium falciparum in vitro. J. Infect. Dis. 2009, 200:1289-1299.
67. Pamplona A., Ferreira A., Balla J., Jeney V., Balla G., Epiphanio S., Chora A., Rodrigues C.D., Gregoire I.P., Cunha-Rodrigues M., Portugal S., Soares M.P., Mota M.M. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat. Med. 2007, 13:703-710.
68. Hebbel R.P., Morgan W.T., Eaton J.W., Hedlund B.E. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Nat. Acad. Sci. USA 1988, 85:237-241.
69. Eltzschig H.K., Thompson L.F., Karhausen J., Cotta R.J., Ibla J.C., Robson S.C., Colgan S.P. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004, 104:3986-3992.
70. Rosenthal P.J. Lessons from sickle cell disease in the treatment and control of malaria. N. Engl. J. Med. 2011, 364:2549-2551.